Our comparative data specific to NTRK gene fusion detection show the feasibility of RNA-based NGS targeted panels on FFPE samples, and the variable TRK expression in NTRK fusion positive tumours, thus voicing a word of caution whenever interpreting this assay and opening questions related to the correlation with response to TRK inhibitors, which remains to be determined. The gene discussed is TPM3; the disease is neoplasm.